TG Therapeutics Inc (TGTX): TG Therapeutics conference call April 1...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	20
Posts	1676
Boards Moderated	0
Alias Born	07/09/2005

stockguard

Re: whytestocks post# 1268

Friday, 03/29/2019 4:23:19 PM

Friday, March 29, 2019 4:23:19 PM

TG Therapeutics conference call April 1 on umbralisib in marginal zone lymphoma
Mar. 29, 2019 4:14 PM ET|About: TG Therapeutics, Inc. (TGTX)|By: Douglas W. House, SA News Editor
TG Therapeutics (NASDAQ:TGTX) will host a conference call on Monday, April 1, at 12:00 pm ET to discuss interim data from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with marginal zone lymphoma (MZL), a type of slow-growing non-Hodgkin lymphoma, who have received at least one prior anti-CD20 regimen.

In February, the company announced that the MZL cohort met the primary endpoint of objective response rate (ORR). The final analysis will be completed later this year after all participants have received at least nine cycles of follow-up.

Shares are up 1% after hours.

https://seekingalpha.com/news/3447018-tg-therapeutics-conference-call-april-1-umbralisib-marginal-zone-lymphoma